Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy

2015 ◽  
Vol 170 (1) ◽  
pp. 195-201 ◽  
Author(s):  
Geoffrey D. McWilliams ◽  
Karen SantaCruz ◽  
Blaine Hart ◽  
Carol Clericuzio
2017 ◽  
Vol 88 (6) ◽  
pp. 423-426 ◽  
Author(s):  
Kanthi Bangalore Krishna ◽  
Pedro Pagan ◽  
Oscar Escobar ◽  
Jadranka Popovic

Noonan syndrome (NS) is associated with short stature. Growth hormone treatment has been FDA approved for use in these patients. Children with NS are at a higher risk of developing benign and malignant proliferative disorders, primary brain tumors being one of them. Since growth hormone therapy can worsen the tumor burden, screening with a brain MRI prior to growth hormone initiation in NS patients is strongly recommended. Here we present two NS patients who developed different primary brain tumors while being on growth hormone therapy.


1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S188-S189 ◽  
Author(s):  
K.P. RODENS ◽  
S.L. KAPLAN ◽  
M.M. GRUMBACH ◽  
W.M. TELLER

1997 ◽  
Vol 86 (9) ◽  
pp. 943-946 ◽  
Author(s):  
J De Schepper ◽  
BJ Otten ◽  
I François ◽  
J-P Bourguignon ◽  
M Craen ◽  
...  

2009 ◽  
Vol 24 (3) ◽  
pp. 238-239
Author(s):  
Giuseppe Piccoli ◽  
Isabel Couto ◽  
Deanna Maynard ◽  
John Germak

Sign in / Sign up

Export Citation Format

Share Document